Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Fitmachen fürs EKG-Befunden - Der Video-Kurs jetzt mit 10 CME-Punkten

Mit den EKG Essentials können Sie in zwölf 10- bis 25-minütigen Video-Tutorials mit dem anerkannten EKG-Experten Priv.-Doz. Dr. med. Carsten Israel Ihre Kenntnisse zu den wichtigsten EKG-Befunden systematisch auffrischen. Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi. Jetzt als Video-Kurs zertifiziert mit 10 CME-Punkten! 
Erweiterte Suche
Anmelden
nach oben
HNO Nachrichten
Erschienen in:

01.02.2018 | Zytokine | Fortbildung

Chronische Rhinosinusitis mit Polypen

Die Polyposis nasi als immunologische Erkrankung

verfasst von: Professor Dr. med. Ludger Klimek, M. Koennecke, S. Plontke, P. Plinkert, M. Praetorius, S. Dazert, B. Wollenberg

Erschienen in: HNO Nachrichten | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die chronische Rhinosinusitis (CRS) mit Polypen gilt als multifaktorielle Erkrankung, eine eindeutige Erklärung wie es zu den Gewebsveränderungen kommt, fehlt noch immer. Die CRS mit Nasenpolypen wird als meist TH2-basierte und eosinophil-dominierte Entzündung beschrieben, bei der verschiedene assoziierte Erkrankungen das Entzündungsmuster verändern können — möglicherweise ein Grund, warum bis jetzt keine einheitliche Therapie entwickelt werden konnte. Künftig könnte sich eine individuell auf den Patienten zugeschnittene, endotypgesteuerte Behandlung als optimal erweisen.
Literatur
1.
Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinology Supplement 2012(23):3 p preceding table of contents, 1-298.
2.
Hastan D, Fokkens WJ, Bachert C, Newson RB, Bislimovska J, Bockelbrink A, et al. Chronic rhinosinusitis in Europe—an underestimated disease. A GA(2)LEN study. Allergy 2011;66 (9):1216-23.
3.
Settipane RA, Peters AT, Chiu AG. Chapter 6: Nasal polyps. American journal of rhinology & allergy 2013;27 Suppl 1:S20–5.CrossRef
4.
Landis BN, Konnerth CG, Hummel T. A study on the frequency of olfactory dysfunction. The Laryngoscope 2004;114(10):1764–9.PubMedCrossRef
5.
Messerklinger W. Background and evolution of endoscopic sinus surgery. Ear, nose, & throat journal 1994;73(7):449–50.
6.
Stammberger H. The evolution of functional endoscopic sinus surgery. Ear, nose, & throat journal 1994;73(7):451, 4-5.
7.
Stuck BA, Bachert C, Federspil P, Hosemann W, Klimek L, Mosges R, et al. [Rhinosinusitis guidelines of the German Society for Otorhinolaryngology, Head and Neck Surgery]. Hno 2007;55(10):758–60, 62-4, 66-77.PubMedCrossRef
8.
Hellquist HB. Nasal polyps update. Histopathology. Allergy and asthma proceedings: the official journal of regional and state allergy societies 1996;17(5):237–42.CrossRef
9.
Davidsson A, Hellquist HB. The so-called ‚allergic‘ nasal polyp. ORL; journal for oto-rhino-laryngology and its related specialties 1993;55(1):30–5.PubMedCrossRef
10.
Couto LG, Fernades AM, Brandao DF, Santi Neto D, Valera FC, Anselmo-Lima WT. Histological aspects of rhinosinusal polyps. Brazilian journal of otorhinolaryngology 2008;74(2):207–12.PubMedCrossRef
11.
Calus L, Van Zele T, Derycke L, Krysko O, Dutre T, Tomassen P, et al. Local inflammation in chronic upper airway disease. Current pharmaceutical design 2012;18(16):2336–46.PubMedCrossRef
12.
Annunziato F, Romagnani S. Heterogeneity of human effector CD4+ T cells. Arthritis research & therapy 2009;11(6):257.CrossRef
13.
Zygmunt B, Veldhoen M. T helper cell differentiation more than just cytokines. Advances in immunology 2011;109:159–96.PubMedCrossRef
14.
Plager DA, Kahl JC, Asmann YW, Nilson AE, Pallanch JF, Friedman O, et al. Gene transcription changes in asthmatic chronic rhinosinusitis with nasal polyps and comparison to those in atopic dermatitis. PLoS One 2010;5(7):e11450.PubMedPubMedCentralCrossRef
15.
Van Zele T, Claeys S, Gevaert P, Van Maele G, Holtappels G, Van Cauwenberge P, et al. Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy 2006;61(11):1280–9.PubMedCrossRef
16.
Kopf M, Le Gros G, Bachmann M, Lamers MC, Bluethmann H, Kohler G. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 1993;362(6417):245–8.PubMedCrossRef
17.
Ouyang W, Ranganath SH, Weindel K, Bhattacharya D, Murphy TL, Sha WC, et al. Inhibition of Th1 development mediated by GATA-3 through an IL-4-independent mechanism. Immunity 1998;9(5):745–55.PubMedCrossRef
18.
Derycke L, Eyerich S, Van Crombruggen K, Perez-Novo C, Holtappels G, Deruyck N, et al. Mixed T helper cell signatures in chronic rhinosinusitis with and without polyps. PloS one 2014;9(6):e97581.PubMedPubMedCentralCrossRef
19.
Danielsen A, Tynning T, Brokstad KA, Olofsson J, Davidsson A. Interleukin 5, IL6, IL12, IFN-gamma, RANTES and Fractalkine in human nasal polyps, turbinate mucosa and serum. European archives of oto-rhino-laryngology: official journal of the European Federation of Oto-Rhino-Laryngological Societies 2006;263(3):282–9.CrossRef
20.
Li Z, Zhang Y, Sun B. Current understanding of Th2 cell differentiation and function. Protein & cell 2011;2(8):604–11.CrossRef
21.
Prussin C, Yin Y, Upadhyaya B. T(H)2 heterogeneity: Does function follow form? The Journal of allergy and clinical immunology 2010;126(6):1094–8.PubMedPubMedCentralCrossRef
22.
Bachert C, Wagenmann M, Hauser U, Rudack C. IL-5 synthesis is upregulated in human nasal polyp tissue. The Journal of allergy and clinical immunology 1997;99(6 Pt 1):837–42.PubMedCrossRef
23.
Bachert C, Gevaert P, Holtappels G, Cuvelier C, van Cauwenberge P. Nasal polyposis: from cytokines to growth. American journal of rhinology 2000;14(5):279–90.PubMedCrossRef
24.
Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N, et al. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 2001;14(6):705–14.PubMedCrossRef
25.
Jones SA. Directing transition from innate to acquired immunity: defining a role for IL-6. Journal of immunology 2005;175(6):3463–8.CrossRef
26.
Kaplanski G, Marin V, Montero-Julian F, Mantovani A, Farnarier C. IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends in immunology 2003;24(1):25–9.PubMedCrossRef
27.
Peters AT, Kato A, Zhang N, Conley DB, Suh L, Tancowny B, et al. Evidence for altered activity of the IL-6 pathway in chronic rhinosinusitis with nasal polyps. The Journal of allergy and clinical immunology 2010;125(2):397–403 e10.PubMedPubMedCentralCrossRef
28.
Tomassen P, Vandeplas G, Van Zele T, Cardell LO, Arebro J, Olze H, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol 2016;137(5):1449–56 e4.PubMedCrossRef
29.
Keswani A, Chustz RT, Suh L, Carter R, Peters AT, Tan BK, et al. Differential expression of interleukin-32 in chronic rhinosinusitis with and without nasal polyps. Allergy 2012;67(1):25–32.PubMedCrossRef
30.
Cho JS, Kim JA, Park JH, Park IH, Han IH, Lee HM. Toll-like receptor 4-mediated expression of interleukin-32 via the c-Jun N-terminal kinase/protein kinase B/cyclic adenosine monophosphate response element binding protein pathway in chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol 2016;6(10):1020–8.PubMedCrossRef
31.
Bai X, Kim SH, Azam T, McGibney MT, Huang H, Dinarello CA, et al. IL-32 is a host protective cytokine against Mycobacterium tuberculosis in differentiated THP-1 human macrophages. Journal of immunology 2010;184(7):3830–40.CrossRef
32.
Dinarello CA, Kim SH. IL-32, a novel cytokine with a possible role in disease. Annals of the rheumatic diseases 2006;65 Suppl 3:iii61–4.PubMedPubMedCentral
33.
Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity 2005;22(1):131–42.PubMed
34.
Li W, Sun W, Liu L, Yang F, Li Y, Chen Y, et al. IL-32: a host proinflammatory factor against influenza viral replication is upregulated by aberrant epigenetic modifications during influenza A virus infection. Journal of immunology 2010;185(9):5056–65.CrossRef
35.
Netea MG, Azam T, Lewis EC, Joosten LA, Wang M, Langenberg D, et al. Mycobacterium tuberculosis induces interleukin-32 production through a caspase- 1/IL-18/interferon-gamma-dependent mechanism. PLoS medicine 2006;3(8):e277.PubMedPubMedCentralCrossRef
36.
Nold MF, Nold-Petry CA, Pott GB, Zepp JA, Saavedra MT, Kim SH, et al. Endogenous IL-32 controls cytokine and HIV-1 production. Journal of immunology 2008;181(1):557–65.CrossRef
37.
Calabrese F, Baraldo S, Bazzan E, Lunardi F, Rea F, Maestrelli P, et al. IL-32, a novel proinflammatory cytokine in chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine 2008;178(9):894–901.PubMedCrossRef
38.
Meyer N, Zimmermann M, Burgler S, Bassin C, Woehrl S, Moritz K, et al. IL-32 is expressed by human primary keratinocytes and modulates keratinocyte apoptosis in atopic dermatitis. The Journal of allergy and clinical immunology 2010;125(4):858–65 e10.PubMedCrossRef
39.
Kang JW, Park YS, Lee DH, Kim MS, Bak Y, Ham SY, et al. Interaction network mapping among IL-32 isoforms. Biochimie 2014;101:248–51.PubMedCrossRef
40.
Chin D, Harvey RJ. Nasal polyposis: an inflammatory condition requiring effective anti-inflammatory treatment. Current opinion in otolaryngology & head and neck surgery 2013;21(1):23–30.CrossRef
41.
Lam EP, Kariyawasam HH, Rana BM, Durham SR, McKenzie AN, Powell N, et al. IL-25/IL-33-responsive TH2 cells characterize nasal polyps with a default TH17 signature in nasal mucosa. J Allergy Clin Immunol 2016;137(5):1514–24.PubMedPubMedCentralCrossRef
42.
43.
Wang YH, Angkasekwinai P, Lu N, Voo KS, Arima K, Hanabuchi S, et al. IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC-activated Th2 memory cells. The Journal of experimental medicine 2007;204(8):1837–47.PubMedPubMedCentralCrossRef
44.
Shin HW, Kim DK, Park MH, Eun KM, Lee M, So D, et al. IL-25 as a novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis. J Allergy Clin Immunol 2015;135(6):1476–85 e7.PubMedCrossRef
45.
Kimura S, Pawankar R, Mori S, Nonaka M, Masuno S, Yagi T, et al. Increased expression and role of thymic stromal lymphopoietin in nasal polyposis. Allergy, asthma & immunology research 2011;3(3):186–93.CrossRef
46.
Liu T, Li TL, Zhao F, Xie C, Liu AM, Chen X, et al. Role of thymic stromal lymphopoietin in the pathogenesis of nasal polyposis. The American journal of the medical sciences 2011;341(1):40–7.PubMedCrossRef
47.
Nagarkar DR, Poposki JA, Tan BK, Comeau MR, Peters AT, Hulse KE, et al. Thymic stromal lymphopoietin activity is increased in nasal polyps of patients with chronic rhinosinusitis. The Journal of allergy and clinical immunology 2013;132(3):593–600 e12.PubMedPubMedCentralCrossRef
48.
Nagarkar DR, Poposki JA, Comeau MR, Biyasheva A, Avila PC, Schleimer RP, et al. Airway epithelial cells activate TH2 cytokine production in mast cells through IL-1 and thymic stromal lymphopoietin. The Journal of allergy and clinical immunology 2012;130(1):225–32 e4.PubMedPubMedCentralCrossRef
49.
Reh DD, Wang Y, Ramanathan M, Jr., Lane AP. Treatment-recalcitrant chronic rhinosinusitis with polyps is associated with altered epithelial cell expression of interleukin-33. American journal of rhinology & allergy 2010;24(2):105–9.CrossRef
50.
Kim DK, Jin HR, Eun KM, Mo JH, Cho SH, Oh S, et al. The role of interleukin-33 in chronic rhinosinusitis. Thorax 2016.
51.
Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunological reviews 2008;223:20–38.PubMedCrossRef
52.
Cherry WB, Yoon J, Bartemes KR, Iijima K, Kita H. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. The Journal of allergy and clinical immunology 2008;121(6):1484–90.PubMedPubMedCentralCrossRef
53.
Castano R, Bosse Y, Endam LM, Desrosiers M. Evidence of association of interleukin-1 receptor-like 1 gene polymorphisms with chronic rhinosinusitis. American journal of rhinology & allergy 2009;23(4):377–84.CrossRef
54.
Beck LA, Stellato C, Beall LD, Schall TJ, Leopold D, Bickel CA, et al. Detection of the chemokine RANTES and endothelial adhesion molecules in nasal polyps. The Journal of allergy and clinical immunology 1996;98(4):766–80.PubMedCrossRef
55.
Davidsson A, Danielsen A, Viale G, Olofsson J, Dell’Orto P, Pellegrini C, et al. Positive identification in situ of mRNA expression of IL-6, and IL-12, and the chemotactic cytokine RANTES in patients with chronic sinusitis and polypoid disease. Clinical relevance and relation to allergy. Acta oto-laryngologica 1996;116(4):604–10.PubMedCrossRef
56.
Allen JS, Eisma R, LaFreniere D, Leonard G, Kreutzer D. Characterization of the eosinophil chemokine RANTES in nasal polyps. The Annals of otology, rhinology, and laryngology 1998;107(5 Pt 1):416–20.PubMedCrossRef
57.
Meyer JE, Bartels J, Gorogh T, Sticherling M, Rudack C, Ross DA, et al. The role of RANTES in nasal polyposis. American journal of rhinology 2005;19(1):15–20.PubMed
58.
Chen YS, Arab SF, Westhofen M, Lorenzen J. Expression of interleukin-5, interleukin-8, and interleukin-10 mRNA in the osteomeatal complex in nasal polyposis. American journal of rhinology 2005;19(2):117–23.PubMed
59.
Kostamo K, Sorsa T, Leino M, Tervahartiala T, Alenius H, Richardson M, et al. In vivo relationship between collagenase-2 and interleukin-8 but not tumour necrosis factor-alpha in chronic rhinosinusitis with nasal polyposis. Allergy 2005;60(10):1275–9.PubMedCrossRef
60.
Scavuzzo MC, Fattori B, Ruffoli R, Rocchi V, Carpi A, Berni R, et al. Inflammatory mediators and eosinophilia in atopic and non-atopic patients with nasal polyposis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2005;59(6):323–9.CrossRef
61.
Wang X, Zhang N, Bo M, Holtappels G, Zheng M, Lou H, et al. Diversity of TH cytokine profiles in patients with chronic rhinosinusitis: A multicenter study in Europe, Asia, and Oceania. J Allergy Clin Immunol 2016;138(5):1344–53.PubMedCrossRef
62.
Poposki JA, Uzzaman A, Nagarkar DR, Chustz RT, Peters AT, Suh LA, et al. Increased expression of the chemokine CCL23 in eosinophilic chronic rhinosinusitis with nasal polyps. The Journal of allergy and clinical immunology 2011;128(1):73–81 e4.PubMedPubMedCentralCrossRef
63.
Bachert C, Van Cauwenberge PB. Inflammatory mechanisms in chronic sinusitis. Acta oto-rhino-laryngologica Belgica 1997;51(4):209–17.PubMed
64.
Fundova P, Funda DP, Kovar D, Holy R, Navara M, Tlaskalova-Hogenova H. Increased expression of chemokine receptors CCR1 and CCR3 in nasal polyps: molecular basis for recruitment of the granulocyte infiltrate. Folia microbiologica 2013;58(3):219–24.PubMedCrossRef
65.
Patel VP, Kreider BL, Li Y, Li H, Leung K, Salcedo T, et al. Molecular and functional characterization of two novel human C-C chemokines as inhibitors of two distinct classes of myeloid progenitors. The Journal of experimental medicine 1997;185(7):1163–72.PubMedPubMedCentralCrossRef
66.
Novak H, Muller A, Harrer N, Gunther C, Carballido JM, Woisetschlager M. CCL23 expression is induced by IL-4 in a STAT6-dependent fashion. Journal of immunology 2007;178(7):4335–41.CrossRef
67.
Peterson S, Poposki JA, Nagarkar DR, Chustz RT, Peters AT, Suh LA, et al. Increased expression of CC chemokine ligand 18 in patients with chronic rhinosinusitis with nasal polyps. The Journal of allergy and clinical immunology 2012;129(1):119–27 e1–9.PubMedCrossRef
68.
Islam SA, Ling MF, Leung J, Shreffler WG, Luster AD. Identification of human CCR8 as a CCL18 receptor. The Journal of experimental medicine 2013;210(10):1889–98.PubMedPubMedCentralCrossRef
69.
Kato A, Peters A, Suh L, Carter R, Harris KE, Chandra R, et al. Evidence of a role for B cell-activating factor of the TNF family in the pathogenesis of chronic rhinosinusitis with nasal polyps. The Journal of allergy and clinical immunology 2008;121(6):1385–92, 92 e1-2.PubMedPubMedCentralCrossRef
70.
Polzehl D, Moeller P, Riechelmann H, Perner S. Distinct features of chronic rhinosinusitis with and without nasal polyps. Allergy 2006;61(11):1275–9.PubMedCrossRef
71.
Patadia M, Dixon J, Conley D, Chandra R, Peters A, Suh LA, et al. Evaluation of the presence of B-cell attractant chemokines in chronic rhinosinusitis. American journal of rhinology & allergy 2010;24(1):11–6.CrossRef
72.
Hadfield PJ, Rowe-Jones JM, Mackay IS. The prevalence of nasal polyps in adults with cystic fibrosis. Clinical otolaryngology and allied sciences 2000;25(1):19–22.PubMedCrossRef
73.
Derycke L, Zhang N, Holtappels G, Dutre T, Bachert C. IL-17A as a regulator of neutrophil survival in nasal polyp disease of patients with and without cystic fibrosis. Journal of cystic fibrosis: official journal of the European Cystic Fibrosis Society 2012;11(3):193–200.CrossRef
74.
Waite JC, Skokos D. Th17 response and inflammatory autoimmune diseases. International journal of inflammation 2012;2012:819467.PubMedCrossRef
75.
Bakhshaee M, Fereidouni M, Mohajer MN, Majidi MR, Azad FJ, Moghiman T. The prevalence of allergic fungal rhinosinusitis in sinonasal polyposis. European archives of oto-rhino-laryngology: official journal of the European Federation of Oto-Rhino-Laryngological Societies 2013;270(12):3095–8.CrossRef
76.
77.
Han JK. Subclassification of chronic rhinosinusitis. The Laryngoscope 2013;123 Suppl 2:S15–27.PubMedCrossRef
78.
Kramer MF, Ostertag P, Pfrogner E, Rasp G. Nasal interleukin-5, immunoglobulin E, eosinophilic cationic protein, and soluble intercellular adhesion molecule-1 in chronic sinusitis, allergic rhinitis, and nasal polyposis. The Laryngoscope 2000;110(6):1056–62.PubMedCrossRef
79.
Peric A, Vojvodic D, Vukomanovic-Durdevid B. Influence of allergy on clinical, immunological and histological characteristics of nasal polyposis. B-Ent 2012;8(1):25–32.PubMed
80.
Baraniuk JN. Pathogenesis of allergic rhinitis. The Journal of allergy and clinical immunology 1997;99(2):S763–72PubMedCrossRef
81.
Scadding G. Cytokine profiles in allergic rhinitis. Current allergy and asthma reports 2014;14(5):435.PubMedCrossRef
82.
Shin SH, Ye MK, Kim YH, Kim JK. Role of TLRs in the production of chemical mediators in nasal polyp fibroblasts by fungi. Auris Nasus Larynx 2016;43(2):166–70.PubMedCrossRef
83.
Feghali CA, Wright TM. Cytokines in acute and chronic inflammation. Frontiers in bioscience: a journal and virtual library 1997;2:d12–26.CrossRef
84.
Stuck BA, Bachert C, Federspil P, Hosemann W, Klimek L, Mosges R, et al. Rhinosinusitis guidelines of the German society for otorhinolaryngology, head and neck surgery. Hno 2007;55(10):758-+.PubMedCrossRef
85.
Peric A, Vojvodic D, Peric AV, Radulovic V, Miljanovic O. Correlation between cytokine levels in nasal fluid and scored clinical parameters in patients with nasal polyposis. Indian journal of otolaryngology and head and neck surgery: official publication of the Association of Otolaryngologists of India 2013;65(Suppl 2):295–300.CrossRef
86.
Nabavi M, Arshi S, Bahrami A, Aryan Z, Bemanian MH, Esmaeilzadeh H, et al. Increased level of interleukin-13, but not interleukin-4 and interferon-gamma in chronic rhinosinusitis with nasal polyps. Allergologia et immunopathologia 2014;42(5):465–71.PubMedCrossRef
87.
Bachert C, Zhang N. Chronic rhinosinusitis and asthma: novel understanding of the role of IgE ‚above atopy‘. Journal of internal medicine 2012;272(2):133–43.PubMedCrossRef
88.
Steinke JW, Liu L, Huyett P, Negri J, Payne SC, Borish L. Prominent role of IFN-gamma in patients with aspirin-exacerbated respiratory disease. The Journal of allergy and clinical immunology 2013;132(4):856–65 e1–3.PubMedPubMedCentralCrossRef
Metadaten
Titel
Chronische Rhinosinusitis mit Polypen
Die Polyposis nasi als immunologische Erkrankung
verfasst von
Professor Dr. med. Ludger Klimek
M. Koennecke
S. Plontke
P. Plinkert
M. Praetorius
S. Dazert
B. Wollenberg
Publikationsdatum
01.02.2018
Verlag
Springer Medizin
Erschienen in
HNO Nachrichten / Ausgabe 1/2018
Print ISSN: 0177-1000
Elektronische ISSN: 2198-6533
DOI
https://doi.org/10.1007/s00060-018-5608-x

Weitere Artikel der Ausgabe 1/2018

HNO Nachrichten 1/2018 Zur Ausgabe

Literatur kompakt

Sinuschirurgie verbessert die Lebensqualität

Industrieforum

Alternative Heilmethoden bei Allergien nur als Ergänzung

Industrieforum

Plattenepithelkarzinom des Kopf-Hals-Bereichs: Zusatznutzen durch Nivolumab

Industrieforum

Die besten Strategien für gesunde Atemwege in jedem Alter

Medizin aktuell

Wie viel Antibiotikum bei kindlicher Streptokokken-Tonsillitis?

Prisma

Die Schatzkästchen der Otologie

Neu im Fachgebiet HNO

Frühe orale Toleranz statt Sensibilisierung über die Haut

Personen mit atopischer Dermatitis haben begleitend häufig Nahrungsmittelallergien. Die geschädigte Hautbarriere spielt eine entscheidende Rolle bei der Sensibilisierung und erschwert die orale Toleranzentwicklung. Umso wichtiger ist die Regeneration der Hautbarriere.

Schutz der Schleimhautbarriere bei chronischer Rhinosinusitis

Die Gewebsumgestaltung der oberen Atemwege („airway remodeling“) bei allergischem Asthma und chronischer Rhinosinusitis mit nasalen Polypen (CRSwNP) ist nach der neuen Nomenklatur allergischer Erkrankungen der EAACI ein eigenständiger gewebespezifischer Mechanismus.

Immunologische Endotypen beim CRSwNP – neue Nomenklatur

„Die chronische Rhinosinusitis mit Nasenpolypen (CRSwNP) zeigt immunologisch ein sehr heterogenes Bild“, wie Prof. Moritz Gröger, LMU-Klinikum München, beim Deutschen Allergiekongress 2024 dargestellt hat. Der immunologische Endotyp sei hierbei mit dem klinischen Phänotyp assoziiert.

So wirkt sich Stress auf atopische Dermatitis aus

Psychische Belastungen und die atopische Dermatitis (AD) bedingen einander, vermittelt über verschiedene Stressmediatoren im Körper. 

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise